The cholera vaccine market is experiencing significant developments driven by rising global health concerns, technological advancements, and strategic collaborations. Here's a comprehensive overview:​

The global cholera vaccine market was valued at USD 60 million in 2022 and grew at a CAGR of 10% from 2023 to 2032. The market is expected to reach USD 155.62 million by 2032. 

🧪 Recent Developments

• Euvichol-S by EuBiologics: In April 2024, EuBiologics Co., Ltd. announced that its new cholera vaccine, Euvichol-S, received WHO prequalification, enhancing global vaccine availability. This development is expected to help produce vaccines at a lower cost, addressing supply shortages. ​

• Emergent BioSolutions & Bavarian Nordic Partnership: In February 2023, Emergent BioSolutions Inc. partnered with Bavarian Nordic, transferring rights to the Vaxchora vaccine and associated manufacturing facilities. Approximately 280 Emergent employees joined Bavarian Nordic as part of this deal. ​

🚀 Market Drivers

• Increasing Cholera Incidences: The rise in cholera outbreaks globally has heightened the demand for vaccines. In 2024, over 249,000 cholera cases were reported, prompting affected countries to request double the vaccine doses compared to the previous year. ​

• Global Health Initiatives: Efforts by international organizations and governments have strengthened vaccination campaigns, aiming to reduce outbreaks and improve public health outcomes. ​

•  

🛑 Market Restraints

• Vaccine Supply Shortages: Despite increased demand, the global cholera vaccine stockpile has been depleted, exacerbating the crisis in regions experiencing outbreaks. ​

• Infrastructure Challenges: Inadequate water and sanitation infrastructure in many regions hampers effective cholera prevention and control efforts. ​

🌍 Regional Segmentation Analysis

• Asia Pacific: This region holds the largest market share due to high incidence rates and growing awareness. Notably, India implemented a program covering 50,000 people using Euvichol-Plus. ​

• North America: While not endemic, North America contributes significantly through funding and support for global health initiatives, including vaccine distribution to cholera-prone areas. ​

📈 Emerging Trends

• Technological Advancements: Recent developments in oral cholera vaccines have improved production efficiency, reducing manufacturing time by 75%. ​

• Collaborative Efforts: Collaborations between companies and international organizations are leading to improved products, manufacturing processes, and supply-chain systems, ensuring last-mile delivery of quality vaccines globally. ​

💡 Top Use Cases

• Travelers: Vaccines like Dukoral and Vaxchora are used by travelers heading to endemic regions. ​

• Mass Immunization Campaigns: Countries like Zambia have launched campaigns targeting large populations to curb outbreaks. ​

⚠️ Major Challenges

• Conflict and Climate Change: Ongoing conflicts and climate-related issues have led to increased cholera outbreaks, with 2024 reporting 804,721 cases and 5,805 deaths. ​

• Healthcare Infrastructure: Many regions lack the necessary healthcare infrastructure to effectively distribute and administer vaccines. ​

🌟 Attractive Opportunities

• Innovative Vaccine Delivery: The introduction of vaccines like Euvichol-Plus in India, packaged in low-density polyethylene unidose packs, represents advancements in vaccine delivery methods. ​

• Expansion in Emerging Markets: There's significant potential for market growth in emerging economies through targeted vaccination programs and infrastructure development. ​

🏢 Key Market Players

• Valneva SE​

• Sanofi S.A.​

• Emergent BioSolutions Inc.​

• PaxVax Inc.​

• EuBiologics Co., Ltd.​

• Shantha Biotechnics Limited​

• Hilleman Laboratories​

• Astellas Pharma Inc.​

• Incepta Vaccine Ltd.​

• Vabiotech ​

For a more detailed analysis, you may refer to the comprehensive report by Nova One Advisor. 

• Market Introduction
• Market Dynamics
• Segment Analysis
• Some of the Key Market Players